Navigation Links
PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
Date:10/27/2008

ANNAPOLIS, Md., Oct. 27 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE ALTERNEXT US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that dosing of volunteers has begun in a U.S. Phase I clinical trial evaluating Protexia(R) for safety and tolerability in humans. Protexia(R), which is produced in the milk of transgenic goats, is a recombinant version of human butyrylcholinesterase (BChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.

The randomized, placebo-controlled, third-party double-blind, dose escalating Phase I clinical trial will study Protexia(R) administered intramuscularly at one and two time points in healthy human volunteers. Approximately 32 subjects will participate in the study, comprised of healthy male and female volunteers between the ages of 18 and 55 years who are willing to give informed consent and are in general good health.

Under the study protocol, either Protexia(R) or a saline control will be administered in escalating doses to five groups of volunteers. Safety data through 14 days post-dosing will be evaluated prior to escalation to a higher dose. Subjects in four of the groups (comprised of six subjects each) will receive a single dose of Protexia(R) and participate in the trial for two and a half months. One group of eight subjects will receive a second dose of Protexia(R) approximately 72 days following the first dose and will participate in the study for approximately five months.

The primary endpoint of the study is an evaluation of the safety, tolerability, pharmacokinetics and immunogenicity of escalating single doses of Protexia(R) given intramuscularly in healthy human volunteers. The secondary endpoint will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of a second dose of Protexia(R) in one dose cohort.

"The initiation of pati
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
4. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
5. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
6. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
9. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
10. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
11. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... LAVAL, Quebec , July 10, 2014  Valeant ... TSX: VRX) today announced it has completed the sale ... Sculptra, and Dysport owned or held by Valeant for ... agreement with Nestle S.A, which recently completed its acquisition ... complete the divestiture of our products to a company ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
(Date:1/15/2014)... 15, 2014 As health officials across the Midwest warn ... pharmacies in Michigan will offer free ... enabling Meijer pharmacists to administer tests and, in some cases, ... physician participating in the study. The ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... , , , , , SAN ... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and ... ALKS ) today announced positive results from a head-to-head ... BYETTA® (exenatide) injection taken twice daily, in patients with type ...
... , , LONDON, Dec. 14 The 2009 Frost ... Market is conferred on SonoScape. The award recipient has effectively ... pricing, and portability - and introduced the S8 hand-carried ultrasound ... compares with that of a regular, high-end, cart-based echo ultrasound ...
Cached Medicine Technology:Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 3
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... survey which was conducted in Delhi, Mumbai, Chennai, Hyderabad and Kolkata ... of the harmful effects of ultra-violet (UV) rays. // The results ... that UV rays affect the eyes. About 73% of the people ... also found that people do not take any precaution to protect ...
... Minister Manmohan Singh underwent a minor surgical procedure on his ... this morning. // ,'The operation on the left ... October 13, 2005. This completes the procedure advised by doctors ... Prime Minister's media advisor Sanjaya Baru said in a statement., ...
... immolation at the Ramlila grounds in New Delhi at a ... // The student had 15 percent burns and was admitted ... Delhi and Kanpur are to go at a hunger strike ... Union Health Ministry has issued orders to nine central medical ...
... from high blood pressure, heart disease and a number ... arteries // , overactive thyroid gland not to take ... there is an increase in the number of cases ... also asked the patients to consult their doctors before ...
... over the past three years has found that increasingly stress ... of the people. // More than 50 percent of the ... condition that increases the risk of heart attack and stroke, ... the people in the age group of 40-70 years were ...
... study conducted by Readers Digest Magazine for a poll it ... and psychic powers. // About 50% of them said that ... surveyed about 1,006 adults and 43% said that they could ... expert. About 50% said that they had dreamt of an ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: